The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...